The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Penny, Melissa A ^a,b   Pemberton Ross, Peter ^a,b   Smith, Thomas A ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Malaria; Model; RTS,S; Simulation; Vaccine

Indexed keywords

MALARIA VACCINE; RECOMBINANT VACCINE; RTS,S-AS01 VACCINE;

ARTICLE; BAYES THEOREM; CHILD; CLINICAL OBSERVATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; FOLLOW UP; HUMAN; INFANT; MALARIA; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; STOCHASTIC MODEL; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; TIME FACTOR; TREATMENT OUTCOME;

CHILD, PRESCHOOL; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALARIA; MALARIA VACCINES; TIME FACTORS; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 84946236060     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0969-8     Document Type: Article

References (31)

1. World Health Organization. World Malaria Report 2013. Geneva: World Health Organization; 2014.
2. RTSS Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31-45.
3. Pemberton-Ross P, Smith TA, Hodel EM, Kay K, Penny MA. Age-shifting in malaria incidence as a result of induced immunological deficit: a simulation study. Malar J. 2015;14:287.
4. Coleman PG, Perry BD, Woolhouse ME. Endemic stability-a veterinary idea applied to human public health. Lancet. 2001;357:1284-6.
5. The RTSS Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;2014(11):e1001685.
6. Penny MA, Galactionova K, Tarantino M, Tanner M, Smith TA. The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models. BMC Med. 2015;13:170.
7. White MT, Bejon P, Olotu A, Griffin JT, Bojang K, Lusingu J, Salim N, Abdulla S, Otsyula N, Agnandji ST, et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med. 2014;12:117.
8. Smith T, Ross A, Maire N, Chitnis N, Studer A, Hardy D, Brooks A, Penny M, Tanner M. Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine. PLoS Med. 2012;9:44.
9. Smith T, Killeen GF, Maire N, Ross A, Molineaux L, Tediosi F, Hutton G, Utzinger J, Dietz K, Tanner M. Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: overview. Am J Trop Med Hyg. 2006;75:1-10.
10. Chitnis N, Hardy D, Smith T. A periodically-forced mathematical model for the seasonal dynamics of malaria in mosquitoes. Bull Math Biol. 2012;74:1098-124.
11. Smith T, Maire N, Dietz K, Killeen GF, Vounatsou P, Molineaux L, Tanner M. Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. Am J Trop Med Hyg. 2006;75:11-8.
12. Maire N, Smith T, Ross A, Owusu-Agyei S, Dietz K, Molineaux L. A model for natural immunity to asexual blood stages of Plasmodium falciparum malaria in endemic areas. Am J Trop Med Hyg. 2006;75:19-31.
13. Ross A, Killeen GF, Smith T. Relationships of host infectivity to mosquitoes and asexual parasite density in Plasmodium falciparum. Am J Trop Med Hyg. 2006;75(Suppl 2):32-7.
14. Ross A, Maire N, Molineaux L, Smith T. An epidemiologic model of severe morbidity and mortality caused by Plasmodium falciparum. Am J Trop Med Hyg. 2006;75:63-73.
15. Smith T, Ross A, Maire N, Rogier C, Trape JF, Molineaux L. An epidemiologic model of the incidence of acute illness in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2006;75:56-62.
16. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, Tatem AJ, Hay SI. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J. 2011;10:378.
17. Penny MA, Maire N, Bever CA, Pemberton-Ross P, Briët OJT, Smith DL, Gething PW, Smith TA. Distributions of malaria exposure in endemic countries in Africa considering country levels of effective treatment. Malar J. 2015;14:384.
18. Center for International Earth Science Information Network (CIESIN) CU. Global Rural-Urban Mapping Project (GRUMP): Urban extents. New York: Palisades; 2004.
19. Open Malaria decay functions. https://github.com/SwissTPH/openmalaria/wiki/ModelDecayFunctions-configuration.
20. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, Bousema T, Drakeley CJ, Ferguson NM, Basanez MG, Ghani AC. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med. 2010;7:e1000324.
21. Bailey NJT. The biomathematics of malaria. London: Charles Griffin and Co Ltd; 1982.
22. Walker PG, White MT, Griffin JT, Reynolds A, Ferguson NM, Ghani AC. Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: a modelling analysis. Lancet Infect Dis. 2015;15:825-32.
23. Eckhoff PA. Malaria parasite diversity and transmission intensity affect development of parasitological immunity in a mathematical model. Malar J. 2012;11:10-1186.
24. Maire N, Aponte JJ, Ross A, Thompson R, Alonso P, Utzinger J, Tanner M, Smith T. Modeling a field trial of the RTS,S/AS02A malaria vaccine. Am J Trop Med Hyg. 2006;75:104-10.
25. Wenger EA, Eckhoff PA. A mathematical model of the impact of present and future malaria vaccines. Malar J. 2013;12:10-1186.
26. Ballou WR. The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol. 2009;31:492-500.
27. White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, Greenwood B, Drakeley C, Gesase S, Lusingu J, Ansong D, et al. Immunogenicity of the RTS,S/AS01 malaria vaccine over time and implications for duration of vaccine efficacy: analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015. doi: 10.1016/S1473-3099(15)00239-X (Epub ahead of print).
28. Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, Lievens M, Leboulleux D, Njuguna P, Peshu N, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med. 2013;368:1111-20.
29. Penny MA, Maire N, Studer A, Schapira A, Smith TA. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS One. 2008;3:e3193.
30. White MT, Griffin JT, Akpogheneta O, Conway DJ, Koram KA, Riley EM, Ghani AC. Dynamics of the antibody response to Plasmodium falciparum infection in African children. J Infect Dis. 2014;210:1115-22.
31. Crowell V, Yukich JO, Briet JT, Ross A, Smith TA. A novel approach for measuring the burden of uncomplicated Plasmodium falciparum malaria: application to data from Zambia. PLoS One. 2013:e57297.